Common Viruses May Wake Dormant Breast Cancer Cells, Study Finds
Some common viruses may re-awaken a very small number of dormant breast cancer cells within our lungs, according to emerging research.
"Dormant cancer cells are like the embers left in an abandoned campfire, and respiratory viruses are like a strong wind that reignites the flames," argues molecular geneticist James DeGregori from the University of Colorado.
Related:
The research began following the COVID-19 pandemic, when DeGregori and his colleagues began to notice a curious uptick in cancer cases.
To find out more, the international team turned to human population studies and mouse models.
They found that patients in remission for cancer in the UK Biobank who tested positive for SARS-CoV-2 later showed a twofold increase in cancer-related death.
"The extent of this increased risk is almost unheard of in epidemiology for cancer," says epidemiologist Roel Vermeulen from Utrecht University in The Netherlands.
"It's a significant effect."
That's not all researchers found, either. Analyzing a separate breast cancer database from the United States, including nearly 37,000 patients, they discovered that a previous SARS-CoV-2 infection was associated with a greater than 40 percent increased risk of metastatic breast cancer in the lungs.
Studies in mice suggest that viruses might be behind the spread.
Influenza and SARS-CoV-2 infections triggered dormant breast cancer cells in mice to proliferate after only days of infection.
Within two weeks, there was "a massive expansion of carcinoma cells into metastatic lesions" by more than 100-fold, write the authors, led by molecular geneticist Shi Chia from the University of Colorado.
"Although species differences warrant caution in interpreting mouse data… collectively, these findings underscore the substantial metastatic risk COVID-19 posed to cancer survivors," warn the team.
For years now, scientists have suspected that some highly common viruses, like the Epstein-Barr Virus (EBV), have the potential to trigger certain cancers.
The human papillomavirus (HPV) is already known to do this. That's why the HPV vaccine has proved so life-changing for millions. It prevents deadly, viral-associated diseases, like cervical cancer.
Since 1936, scientists have been searching for a virus that triggers breast cancer in a similar way, mostly in mice and human population studies.
High-risk viruses have been detected in human breast cancer samples. EBV, for instance, is five times higher in breast cancer tissue than in normal tissue.
But while the idea that viruses may predispose us to cancer is plausible, research in human cells is limited, and the mechanism underlying the disease spread remains undetermined.
The immune system's response to viruses could possibly play a role.
After initial remission, a tiny number of breast cancer cells can remain dormant in lung, bone, and liver tissue.
Sometimes, inflammation can wake these cancer cells up – and viral respiratory infections, like the flu and COVID-19, can cause inflammation.
In the current mouse experiments, the influenza A virus only reawakened dormant cancer cells in the lung if they triggered an increase in inflammatory cytokines, such as IL-6.
The same was true of the coronavirus.
The findings suggest that the immune system's response to viruses breeds the perfect environment for cancer to proliferate.
"What our data suggest is that if you are a cancer patient who has these dormant cells, you may end up living a normal life and dying with these dormant cells, instead of dying because those dormant cells awakened," says DeGregori.
"But if you get a respiratory virus like influenza or COVID, your chance of dying from those dormant cells awakening is much greater."
If that's true, then it will be vital to protect the millions of breast cancer survivors out there who may face an increased risk of relapse if they get sick.
Further research is needed to see if vaccination against influenza or COVID-19 can help.
The study was published in Nature.
Related News
Study Reveals The Shocking Amount of Plastic We Breathe in Every Day
Researchers Identified New Blood Group After 50 Year Mystery
Sleepiness Could Be Triggered by a Power Overload in Our Brain
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
10 minutes ago
- Forbes
MIT Spinout Strand Therapeutics Raises $153 Million To Make Cancerous Tumors Light Up
Strand Therapeutics founders Jake Becraft (left) and Tasuku Kitada Jon Chomitz As a grad student in biological engineering at MIT, Jake Becraft had an idea that could change the way we treat cancer: What if genes could be turned on and off like light switches? Thinking it through a bit further, he envisioned 'circuits' in which messenger RNA (mRNA), which carries the instructions for making proteins to cells, could be programmed to cause cancerous tumors to reveal themselves to the body's immune system. It was an idea at the cutting-edge of science, and when Becraft cofounded Cambridge, Mass.-based Strand Therapeutics to pursue it there was no guarantee of success. Now, eight years later, Strand seems on the cusp of it. Strand's preliminary phase 1 clinical trial showed that its first programmable mRNA drug is not only safe, but can shrink tumors in cancer patients who had otherwise run out of treatment options. 'It shocked even us,' Becraft told Forbes. 'You hope something happens, but you don't expect to see a huge response because these patients have already proven to have cancers so resistant to treatment.' With those results, Strand Therapeutics raised $153 million in new venture funding led by Swedish investment giant Kinnevik to build out its programmable mRNA therapeutics pipeline. Other investors include VC firms Iconiq and Playground Global; Regeneron Ventures, the venture arm of Regeneron Pharmaceuticals; and drugmakers Amgen and Eli Lilly. The investment brings Strand's total funding to $250 million and its valuation to an estimated $550 million. That number pales in comparison to the stratospheric valuations of today's AI startups, but it's a significant one for a clinical-stage biotech that was worth $359 million at its last round, in November 2024, according to venture-capital database PitchBook. The funding comes at a time when biotech firms have been struggling to raise money and the public markets are filled with zombie biotechs that are trading below their cash on hand. Strand, which hopes to get its first therapy on the market by 2030, does not yet have revenue. Most people know mRNA as the backbone of the vaccines from Moderna and BioNTech during the Covid-19 pandemic. Despite their success, those vaccines have become a political football, with Health & Human Services Secretary Robert F. Kennedy Jr. announcing on Tuesday that he was pulling $500 million of federal funding from mRNA vaccine projects. But mRNA could potentially be used to treat a variety of diseases, from cancer to heart disease. Unlike Covid-19 vaccines, which send instructions to a cell's nucleus to create antigens for a virus, Strand's mRNA therapeutics instruct tumors to produce signals that make them visible to the body's immune system—essentially lighting them up–so that it can fight back. 'The clinical results blew us away,' said Ala Alenazi, an investment manager at Kinnevik, who will join Strand's board of directors with the deal. 'They have been able to prove out these ambitions that had stayed in textbooks.' 'What's become very clear in the past year or year-and-a-half is that the age of messenger RNA and genetic medicines is finally here.' Jake Becraft, cofounder and CEO, Strand Therapeutics Becraft, who is now 34, calls himself 'a reluctant biotech executive.' In 2017, he and Tasuku Kitada, the company's president and head of research and development—the first scientist to create synthetic mRNA gene circuits while working as a researcher at MIT—spun Strand out of MIT. Becraft's Ph.D. advisor, Ron Weiss, a professor of biological engineering whose work focuses on engineering cells and building circuits, was also a cofounder and remains an advisor to the company. In 2019, Strand scored seed funding with Playground leading the round. Its valuation then was just $15.5 million, according to venture-capital database PitchBook. 'They were young Ph.D.s with amazing ideas when we first met with them,' said Jory Bell, a general partner at Playground Global. Becraft has long believed that the biggest barrier to new and personalized medicines is delivery. Today, many therapies are administered by 'brute forcing the proteins into the right cells,' requiring lengthy hospital stays for patients and high costs for insurers, he said. 'What we want to do is deliver proteins that have a therapeutic outcome into a cancer cell or immune cell or into the bone marrow,' he said. That targeting allows the treatment to be potent where it's needed without being toxic where it isn't. 'What's become very clear in the past year or year-and-a-half is that the age of messenger RNA and genetic medicines is finally here,' he said. 'We see that as the path to how we will build medicines in the future.' Consider the first protein that Strand is working with, an immune system stimulant called interleukin 12, or IL-12. It's promising as a cancer immunotherapy, but so far its toxicity has outweighed any anti-cancer benefits. Without targeting, 'it is ineffective or toxic,' Becraft said. 'You want effective and non-toxic.' The results of Strand's study of 22 cancer patients showed it was possible to use targeting to create a potent therapy that wasn't toxic, he said. 'From the very first patients we dosed, we started to see the tumors shrinking,' he said. 'They have been able to prove out these ambitions that had stayed in textbooks.' Ala Alenazi, investment manager, Kinnevik Referring to a contrast dye scan of a patient with stage 4 melanoma, Becraft noted tumors, indicated with black dots, across the body. A second scan of the same patient after treatment with Strand's mRNA drug revealed a stunning improvement. 'The only dot left was where the contrast agent was injected in their arm,' Becraft said. 'I don't think anyone expects that. This was very shocking.' But even with results like this, it's a long road from early clinical trials to commercialization. Strand now plans to use its new influx of funds to conduct additional clinical research with the hopes of getting its first drug approved by 2030. The company also has a few other pre-clinical mRNA therapies in its pipeline, including one that gets infused through a patient's bloodstream rather than injected into a tumor. That would allow it to potentially be used for additional types of cancer that are harder to reach, such as lung cancer. 'We can rewire the way we treat cancer,' Becraft said. 'We think we are just on the precipice of what this technology can do.' MORE FROM FORBES Forbes How A 60-Year-Old Drug Developer Built A $4.4 Billion Biotech Treating 'Butterfly Skin Disease' By Amy Feldman Forbes This AI Founder Became A Billionaire By Building ChatGPT For Doctors By Amy Feldman Forbes How AI And Mini-Organs Could Replace Testing Drugs On Animals By Alex Knapp Forbes Fear Of Super Intelligent AI Is Driving Harvard And MIT Students To Drop Out By Victoria Feng
USA Today
3 hours ago
- USA Today
RFK Jr. defunds mRNA vaccine research. His anti-vax policies will kill people.
It's ridiculous that Kennedy is in this position following a lifetime of gargling conspiratorial and dangerous health nonsense, but his actions are now deadly serious. In his ongoing crusade to make America sicker and dumber, Health and Human Services Secretary (I bristle every time I type that title) Robert F. Kennedy Jr. has axed about $500 million in vital mRNA vaccine research funding. It's the latest salvo in Kennedy's war against science, and it's about as predictably stupid as any of the Neanderthal-brained things he has done since President Donald Trump foisted him on the American public. (My apologies to any Neanderthals offended by the comparison.) You might recall being fortunate beyond measure to receive mRNA vaccine shots during the COVID-19 pandemic. The Nobel Prize-winning vaccine development saved millions of lives globally and was hailed by Trump himself as a 'medical miracle.' 'This may be the most dangerous public health judgment that I've seen' Messenger RNA, or mRNA, vaccines are far more nimble and easier to produce and alter than traditional vaccines, so continued development is seen as crucial ‒ not just for future pandemics but for everything from responding to bioterrorism attacks to cancer prevention. Michael Osterholm, head of the Center for Infectious Disease Research and Policy at the University of Minnesota, told NPR this when asked about Kennedy's mRNA funding decision: 'This may be the most dangerous public health judgment that I've seen in my 50 years in this business. ... It is baseless, and we will pay a tremendous price in terms of illnesses and deaths.' Every day RFK Jr. is in charge is a bad day for science In a New York Times report, University of Pennsylvania immunologist Scott Hensley, who has been researching an mRNA flu vaccine, said: 'This is a bad day for science.' That can be said about every day as long as we have a wholly unqualified anti-vaccine nutter like Kennedy in charge of America's health. And remember, as with all things RFK Jr., his 'concerns' and 'fears' about mRNA vaccines are wholly unfounded and not supported by science. They are safe and have been studied for decades. It's ridiculous that Kennedy is in this position following a lifetime of gargling conspiratorial and dangerous health nonsense, but his actions are now deadly serious, and they're often cloaked by the daily insanity spun up by Trump himself, from tariffs to migrant cruelty to the Jeffrey Epstein scandal. Out go the smart people, in come the vaccine skeptics In June, Kennedy fired all 17 members of the Advisory Committee on Immunization Practices and replaced them with people he handpicked (that's a red flag if I've ever seen one), including several vaccine skeptics. Now they're reexamining your children's vaccine schedule and echoing baseless fears heard in anti-vax circles for years. Kennedy is also reportedly considering getting rid of all members of the U.S. Preventive Services Task Force, which gives guidance to doctors and health insurers on preventive medicine. Dr. Thomas Lew, an assistant clinical professor of medicine at the Stanford University School of Medicine and frequent contributor for USA TODAY Opinion, told CBS News: "This will greatly damage all the work we've done in preventative care, making people sicker, and driving up costs and premiums. To put it mildly, this is extremely concerning ‒ and doing the opposite of making America healthy.' Kennedy is so bad for health that he's being sued by major medical groups Kennedy has removed the COVID-19 vaccine from the recommended immunization schedule for healthy children and pregnant women, prompting a lawsuit from leading medical groups like the American Academy of Pediatrics and the American College of Physicians. At the end of March, the highly respected top vaccine regulator at the Food and Drug Administration was forced out, and wrote in his resignation letter: 'It has become clear that truth and transparency are not desired by the secretary, but rather he wishes subservient confirmation of his misinformation and lies.' Food inspections? Hand washing? What's next to come under RFK Jr.'s ax? Whether through Trump's magical branding skills or Republican malpractice or both, Kennedy was able to take on enough of a veneer of credibility to become health secretary. But he is still the same raw-milk-guzzling, roadkill-eating, vaccine-alarmist dipstick he was for all those years when his gibberish was nothing more than a punchline for jokes about conspiracy-addled loons. And he is now doing things that are making us fundamentally less safe, whether by sowing doubt about vaccines, derailing medical research or curbing food safety inspections. Kennedy's policies are almost certainly going to kill people A year ago, if you asked me and many other sane people to come up with the most irresponsible public figure to put in charge of America's health, we would have said RFK Jr. And here we are, staring down radical changes inspired not by science but by suspicion and opportunistic hearsay. The ineptitude and absurdity of the Trump administration can be almost laughable at times. But I'm convinced people will die because of Kennedy's policies, weirdo worldviews and actions. And I'm not laughing a bit. Follow USA TODAY columnist Rex Huppke on Bluesky at @ and on Facebook at
The Hill
6 hours ago
- The Hill
Cuban animal lovers struggle to feed stray cats and dogs as economic crisis bites
HAVANA (AP) — Every afternoon, 81-year-old Nélida Pérez begins her familiar walk down the cobblestone streets of Old Havana, a procession of hungry cats trailing close behind her. For years, Pérez has taken it upon herself to feed some of the street cats that roam this part of town, which is also one of the most popular tourist spots in the Cuban capital. She once relied on her own food or restaurant donations, but as the island's economic situation worsened and tourism declined, it has become increasingly difficult to provide for them. 'I have never in my life asked anyone for a plate of food to feed my cats,' Pérez told The Associated Press. 'Now I see myself in difficulties because there is no tourism and there is an economic crisis.' Since 2020, Cuba has faced a worsening economic crisis, driven by COVID-19 shutdowns, stricter U.S. sanctions, and an internal monetary reform that triggered inflation. Although the government provides vaccines, sterilization and some free clinics, it does not have the means to provide shelter and food for street cats and dogs. While official data is unavailable, activists say that many pet lovers have turned their homes — even small apartments — into shelters, but they are struggling to keep up with the demand and provide adequate care. 'The streets will kill them,' said Bárbara Iglesias, a 51-year-old pharmacist who adopted five dogs and has rescued and found homes for a dozen others. Iglesias explained that the hardest part is getting food. A 20-kilo (44-pound) bag of dog food, which lasts one dog for about 45 days, costs around $80 — a sum that is out of reach for most. This forces people to feed animals with pig organ meat (offal), chicken parts or mince meat — which are also not easy to obtain. On top of that, annual vaccines cost about $20 and a vet visit is another $10, all while the average monthly salary on the island is only about $12. Experts say that the abandonment of animals in Cuba is a result of several factors, including rising food and medicine prices, the migration of hundreds of thousands of Cubans in the last five years, and a high mortality rate among older adults. 'People are more focused on their problems, which are numerous: Cubans don't have water, they don't have electricity, and getting food is becoming increasingly difficult,' said Annelie González, one of the leaders of the Aldameros Project, a cat colony located in a park in Havana's historic center. 'Having an animal in your care involves feeding and caring,' said González, 36, who works as a restaurant manager and spends much of her income on the cats. She and a small group of volunteers began feeding 15 cats in Aldameros Park at the beginning of the pandemic. Today, they care for more than 150. Over the years, through their own efforts and some donations, they were able to install water pumps, pens for special cases, and cages for the kittens. González points to a number that she said reveals the shocking scale of the problem: at the start of the decade, roughly three abandoned cats appeared in the park each week. This year, that figure has soared to 15 per day. Back in Old Havana, Pérez recounts with sadness how she has seen people mistreat, beat and even kill stray cats. 'As long as I'm alive and healthy, and people help me,' she vowed, 'I'll always find them something to eat.'
